Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs

Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs

The World Health Organization (WHO) recommends periodic assessment of the therapeutic efficacy of praziquantel (PZQ) to detect reduced efficacy that may arise from drug resistance in schistosomes. In this multi-country study (2014), we assessed the therapeutic efficacy of a single oral dose of PZQ (...

Full description

Bibliographic Details
Main Authors:	B. Levecke, J. Vlaminck, L. Andriamaro, S. Ame, V. Belizario, A. Degarege, D. Engels, B. Erko, A.D. Garba, G.M. Kaatano, Z. Mekonnen, A. Montresor, P. Olliaro, O.S. Pieri, M. Sacko, S.O. Sam-Wobo, L.A. Tchuem Tchuenté, J.P. Webster, J. Vercruysse
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	International Journal for Parasitology: Drugs and Drug Resistance
Subjects:	schistosomiasis Mass drug administration programs Praziquantel Drug efficacy Anthelmintic resistance Egg reduction rate
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211320720300348

Similar Items

Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel
by: Eglal I. Amer, et al.
Published: (2022-03-01)

Praziquantel degradation in marine aquarium water
by: Amber Thomas, et al.
Published: (2016-04-01)

Solid dispersions with hydrogenated castor oil increase solubility, dissolution rate and intestinal absorption of praziquantel
by: Marco Vinicius Chaud, et al.
Published: (2010-09-01)

Praziquantel use in aquaculture – Current status and emerging issues
by: Luke J. Norbury, et al.
Published: (2022-04-01)

Praziquantel–Clays as Accelerated Release Systems to Enhance the Low Solubility of the Drug
by: Ana Borrego-Sánchez, et al.
Published: (2020-09-01)

The effects of subcurative praziquantel treatment on life‐history traits and trade‐offs in drug‐resistant Schistosoma mansoni
by: Mafalda Viana, et al.
Published: (2018-04-01)

Praziquantel and Moxidectin pharmacokinetics in dogs after Helmimax administration
by: A. A. Smirnov, et al.
Published: (2023-01-01)

Design, Synthesis and Evaluation of Praziquantel Analogues and New Molecular Hybrids as Potential Antimalarial and Anti-Schistosomal Agents
by: Freddy Mugisho Kasago, et al.
Published: (2023-07-01)

What is required in terms of mass drug administration to interrupt the transmission of schistosome parasites in regions of endemic infection?
by: RM Anderson, et al.
Published: (2015-10-01)

Pharmacogenetics of Praziquantel Metabolism: Evaluating the Cytochrome P450 Genes of Zimbabwean Patients During a Schistosomiasis Treatment
by: Grace Zdesenko, et al.
Published: (2022-06-01)

Preparation and characterisation of Dextran-70 hydrogel for controlled release of praziquantel
by: Flávio dos Santos Campos, et al.
Published: (2013-03-01)

Schistosomiasis in School Age Children in Sierra Leone After 6 Years of Mass Drug Administration With Praziquantel
by: Yakuba M. Bah, et al.
Published: (2019-02-01)

Comparação entre praziquantel e oxamniquine no tratamento da esquistossomose mansoni
by: Antônio Emanuel, et al.
Published: (1983-06-01)

Two-year longitudinal survey reveals high genetic diversity of Schistosoma mansoni with adult worms surviving praziquantel treatment at the start of mass drug administration in Uganda
by: Christina L. Faust, et al.
Published: (2019-12-01)

Coverage and predictors of the uptake of the mass drug administration of praziquantel chemotherapy for schistosomiasis in a selected urban setting in Zambia
by: Felix Nzonzi Kiesolo, et al.
Published: (2023-04-01)

Baixa eficácia da associação oxamniquine e praziquantel na cura da esquistossomose mansônica
by: R. Dietze, et al.
Published: (1986-12-01)

Treatment of hepatic and pulmonary hydatidosis with albendazole and praziquantel
by: Popova G., et al.
Published: (2023-12-01)

In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium
by: Jana Kovač, et al.
Published: (2017-08-01)

Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome
by: Pierre H. H. Schneeberger, et al.
Published: (2018-03-01)

Urogenital schistosomiasis in three different water access in the Senegal river basin: prevalence and monitoring praziquantel efficacy and re-infection levels
by: Bruno Senghor, et al.
Published: (2022-12-01)

Tentativa de controle de Hymenolepis nana através de tratamentos clínicos repetidos, com praziquantel, em uma comunidade fechada The use of repeated praziquantel treatments in an attempt to control Hymenolepis nana in an orphanage
by: R. S. Rocha, et al.
Published: (1981-08-01)

Once a year school-based deworming with praziquantel and albendazole combination may not be adequate for control of urogenital schistosomiasis and hookworm infection in Matuga District, Kwale County, Kenya
by: Sammy M Njenga, et al.
Published: (2014-02-01)

Efficacy of Single-Dose Praziquantel for the Treatment of <i>Schistosoma mansoni</i> Infections among School Children in Rwanda
by: Joseph Kabatende, et al.
Published: (2023-09-01)

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of <i>Schistosoma mansoni</i> Infection
by: Omary Mashiku Minzi, et al.
Published: (2021-04-01)

Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya
by: G.C. Coles, et al.
Published: (2001-12-01)

The immunopathology of human schistosomiasis-III: immunoglobulin isotype profiles and response to praziquantel
by: Romelia M Ramírez, et al.
Published: (1996-10-01)

Use of wogonin as a cooperative drug with praziquantel to better combat schistosomiasis
by: Ho Yin Pekkle Lam, et al.
Published: (2022-08-01)

Comparação entre praziquantel e oxamniquine no tratamento da esquistossomose mansoni
by: Antônio Emanuel, et al.
Published: (1983-06-01)

In vitro anthelmintic activity of nitazoxanide in comparison to praziquantel against Eurytrema coelomaticum
by: Rafael Luiz Olivo, et al.
Published: (2022-10-01)

Síntese do anti-helmíntico praziquantel,a partir da glicina
by: Novaes Maria Rita Carvalho Garbi, et al.
Published: (1999-01-01)

Cocrystals of Praziquantel with Phenolic Acids: Discovery, Characterization, and Evaluation
by: Shiying Yang, et al.
Published: (2022-03-01)

In vitro and in vivo human metabolism and pharmacokinetics of S‐ and R‐praziquantel
by: Nyasha Nicole Kapungu, et al.
Published: (2020-08-01)

In vitro and in vivo activities of DW-3-15, a commercial praziquantel derivative, against Schistosoma japonicum
by: Xiaoli Wang, et al.
Published: (2019-05-01)

Praziquantel is an effective drug for the treatment of Schistosoma Mansoni infection among school-aged children in Northwest Ethiopia
by: Addisu Tesfie, et al.
Published: (2020-04-01)

Schistosomiasis control in Senegal: results from community data analysis for optimizing preventive chemotherapy intervention with praziquantel
by: Boubacar Diop, et al.
Published: (2023-11-01)

Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya--Reply to Drs. Coles, Liang, and Doenhoff
by: C. H. King, et al.
Published: (2001-12-01)

Guidelines for the diagnosis and treatment of schistosomal myeloradiculopathy Orientações sobre o diagnóstico e tratamento da mielorradiculopatia associada à esquistossomose
by: José Roberto Lambertucci, et al.
Published: (2007-10-01)

TRP drop, TRP drop: a steady patter of anti-schistosomal target illumination
by: Daniel J. Sprague, et al.
Published: (2024-02-01)

Baixa eficácia da associação oxamniquine e praziquantel na cura da esquistossomose mansônica
by: R. Dietze, et al.
Published: (1986-12-01)

Safety of topical administration of fluralaner plus moxidectin concurrently with praziquantel in cats
by: Feli M. Walther, et al.
Published: (2018-11-01)